BFM
UTHR icon

Boothbay Fund Management’s United Therapeutics UTHR Stock Holding History

Boothbay Fund Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-86,900
Closed -$36.4M – 2394
2025
Q3 		$36.4M Buy
+86,900
New +$29.2M 0.53% 17

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Boothbay Fund Management's UTHR Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in United Therapeutics (UTHR) in Q2 2026: 782 shares worth $424K. The stake represents 0.01% of the portfolio and ranks #1599 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in UTHR as recently as Q3 2025.

Boothbay Fund Management first reported a position in UTHR in Q1 2017 and has held it in 9 quarters since. The position peaked at $1.58M in Q1 2021. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Boothbay Fund Management held 782 shares of United Therapeutics worth $424K as of Q2 2026.
  • United Therapeutics was a new Boothbay Fund Management position in Q2 2026.
  • United Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1599 holding.
  • Boothbay Fund Management first reported a position in United Therapeutics in Q1 2017 and has held it in 9 quarters since.
  • Boothbay Fund Management's United Therapeutics position peaked at $1.58M in Q1 2021.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.